dc.contributor.author | Jamal Bennour, Mohammed | |
dc.date.accessioned | 2020-09-28T10:30:09Z | |
dc.date.available | 2020-09-28T10:30:09Z | |
dc.date.issued | 2019-11-21 | |
dc.identifier.uri | http://repository.limu.edu.ly/handle/123456789/2024 | |
dc.description | Amyotrophic lateral sclerosis (ALS) is the most common form of the
neurodegeneration , is progressive and fatal neuromuscular disease , the disease
characterized by the degeneration of motor neurons in the brain and spinal cord ,
when the motor neurons die , the ability of the brain to control muscle movement lost,
the people loss the ability to speak , move , eat , breath .
Approximately half of (ALS) patients die within 3-5 years of symptoms onset , the
(ALS) usually strikes people between the age 40-70 , the disease is discovered by
French doctor named ( jean-martin charcot) , “ Amyotrophy “ refers to the atrophy of
the muscle fibers , which are denervated as their corresponding anterior horn cell
degenerate , “ Lateral sclerosis” refers to hardening of the anterior and lateral
corticospinal tracts as motor neurons in these areas degenerate and are replaced by
gliosis . | en_US |
dc.description.abstract | Background: Amyotrophic lateral sclerosis (ALS) is a progressive and fatal
neuromuscular disease that affects approximately 5 of every 100,000 individuals,
Approximately half of ALS patients die within 30 mo of symptom onset and the
majority do not survive beyond 5 years, Currently, riluzole and edaravone are the
only United States Food and Drug Administration (FDA)–approved treatment options
Methods: Outcome (the change in ALS Functional Rating Scale–Revised,
ALSFRSR, from baseline) was projected for placebo patients through 48 weeks and
compared with 48-week edaravone or 24-week edaravone after switching from
placebo.
Results: A total of 123 patients received open-label treatment (65
edaravoneedaravone; 58 placebo-edaravone). The projected ALSFRS-R decline for
placebo from baseline through week 48 was greater than for 48-week edaravone
(P < .0001). For patients switching from placebo to edaravone, ALSFRS-R slope
approached that of continued edaravone for 48 weeks. ALSFRS-R decline did
not differ between actual and projected edaravone through week 48.
Conclusions: Compared with placebo, these analyses suggest that edaravone is
beneficial in ALS patients even after 6 mo of receiving placebo, and efficacy is
maintained for up to 1 year. | en_US |
dc.language.iso | en | en_US |
dc.publisher | faculty of Basic Medical Science - Libyan International Medical University | en_US |
dc.rights | Attribution 3.0 United States | * |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/us/ | * |
dc.title | Advanced Treatment of Amyotrophic Lateral Sclerosis (ALS) | en_US |
dc.type | Other | en_US |